SHL Highlights the Importance of Scalable Manufacturing Capabilities
pharmafile | August 6, 2013 | News story | Manufacturing and Production | auto injector, auto injectors, autoinjector, autoinjector manufacturing, shl capaacilities, shl expansion
As demand for self-injection devices such as auto injectors and pen injectors continues to rise, drug delivery device suppliers must design manufacturing operations that are scalable – especially for key capabilities such as molding and material handling systems. SHL, a leader in this field, has strived to ensure that capacity is always available to adapt to the changing demands of the market and to satisfy the risk mitigation requirements of our clients.
SHL General Manager Frank Isaksson commented on the recent expansion activities at SHL facilities, “We have worked closely with our suppliers to design each of our facilities for maximum scalability. Just recently we added several new lines of molding machines and also installed additional material handling systems. In fact, our facility management team will have new production areas set up for expansion well in advance of receiving any equipment. And, based on our experience, will always be expanding our molding and material handling systems, in addition to tooling, metrology and automation. Knowing this now, we can prepare in advance. The teams involved in these areas are experienced and always looking into ways to optimize production and introduce new technologies to maximize output. In addition, we continue to invest heavily in employee-centric training programs for experienced staff and newcomers, as well as forward looking intern and apprentice programs.”
What all this means to biopharmaceutical customers is that SHL will have the capacity to produce auto injectors, pen injectors and inhaler systems even if demand increases beyond initial forecasts. Communication between all partners is vital regarding ongoing forecasts, especially with several injectable biologics commanding valuations in the several billions USD.
About SHL
SHL is the world’s largest privately-owned designer, developer and manufacturer of advanced drug delivery devices such as auto injectors and pen injectors. We have over 2,400 staff globally, with our primary design centers located in the USA and Sweden and manufacturing centers located in Asia. SHL supplies auto injectors, pen injectors and inhaler systems to global pharmaceutical and biotech companies. Significant investment in R&D has enhanced our broad pipeline of “next generation” drug delivery systems. These innovative devices include a range of disposable and reusable injectors with fixed or variable dosing, enhanced precision and the ability to accommodate high viscosities.
Our organization consists of several distinct group companies:
SHL Medical
Designs, develops and manufactures advanced drug delivery devices for leading pharmaceutical and biotech companies
SHL Healthcare
Develops and manufactures equipment solutions for home, hospital and long term care use
SHL Technologies
Provides contract manufacturing and engineering services for the production of complex medtech and industrial products
SHL Pharma
Provides final assembly, labeling and packaging services of drug delivery devices to the pharmaceutical and biotechnology industries
For additional information visit www.shl-group.com or contact us at info@shl-group.com
SHL Media Contact
Steven R. Kaufman
Marketing Director
+886 32170303
pr@shl-group.com
Related Content
Novartis secures US rights to Adamis’ epinephrine auto injector
Novartis has penned an agreement with Adamis Pharmaceuticals to commercialise and distribute the latter’s epinephrine …
FDA unveils guidelines to help generic medical device versions reach the market
The scandal surrounding Mylan’s price-hiking of its flagship EpiPen epinephrine auto-injector was the news of …
SHL to Present at Pharmapack Symposium Taiwan 2017
Olle Ljungquist, Senior Scientist at SHL Group, will give a talk on the “Requirements and …
